

Hiroaki Tanaka and Hadi Abderrahim appointed Partners at Innogest Capital

The two pharma executives to join the company's healthcare practice

MILAN (ITALY), DECEMBER 4th 2019 – **Hiroaki Tanaka** and **Hadi Abderrahim** have been appointed partners by Innogest SGR's Board of directors. They will join Claudio Giuliano and Giovanni Leo as senior team within Innogest's healthcare practice, and strengthen specifically the oncology and precision medicine team, one of the signature verticals of the investment firm.

Hiroaki Tanaka is an expert in precision medicine and an investor. He has been Head of personalized medicine at Debiopharm, Head of stratified medicine at Merck Serono, Director of market development & strategy at Serono, Vice president of bioinformatics at Genset Corp, the Nasdaq-listed pioneer in human genome (later acquired by Serono). Hiroaki is based in Geneva, Switzerland.

Hadi Abderrahim is an executive manager based in California, with over 20 years of experience and a background in personalized and precision medicine both in biotech and pharma. He has been Head of healthcare strategy at the Qatar Foundation Research & Development, Director and Head of genetics and biomarker for Merck Serono, Head of genetics & genomic platforms at Genset Corp. (later Serono Genetics Institute). Trained between France and the United States, Abderrahim holds a Medical Doctor degree and a PhD in Human Genetics from the University of Paris and a specialization in Disease Genetics from Stanford University. Hadi is based in San Francisco, California.

«We're proud we can count on Hadi and Hiroaki to build a solid organization at the crossroad between precision medicine and oncology. Hadi and Hiroaki have been Venture Partner with our firm for a while, and now can contribute on a totally new level as Partners», said **Claudio Giuliano**, founder of Innogest.

«I am glad to join Innogest and to work with an accomplished team to promote personalized medicine through investments and executive support to startups in oncology», commented **Hiroaki Tanaka**.

«I look forward to contributing to Innogest healthcare practice, with a special emphasis on precision medicine oncology and to strengthen our position in the USA», said **Hadi Abderrahim**.

Innogest (www.innogestcapital.com) is a Venture Capital firm based in Turin, Milan, Geneva and San Francisco. It currently manages about €200 million of capital, across technology and lifescience.

For further information and requests of interview:

Sergio Maistrello – Press Office (sergio.maistrello@innogestcapital.com, +39 338 4649958)